SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                   FORM 8-A/A

                      AMENDING FORM 8-A FILED INITIALLY ON

                                  JULY 18, 2000

                FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES

                     PURSUANT TO SECTION 12(b) OR (g) OF THE

                         SECURITIES EXCHANGE ACT OF 1934

                          Miravant Medical Technologies

             (Exact name of Registrant as specified in its charter)

         Delaware                                   77-0222872
(State of incorporation or organization)        (IRS Employer I.D. No.)

                    336 Bollay Drive, Santa Barbara, CA 93117

                    (Address of principal executive offices)

If this form relates to the  registration  of a class of securities  pursuant to
Section  12(b)  of  the  Exchange  Act  and is  effective  pursuant  to  General
Instruction A.(c), check the following box.

If this form relates to the  registration  of a class of securities  pursuant to
Section  12(g)  of  the  Exchange  Act  and is  effective  pursuant  to  General
Instruction A.(d), check the following box.

Securities Act registration statement file number to which this form relates (if
applicable): Not applicable.

Securities to be registered pursuant to Section 12(b) of the Act:

                                      None

                                (Title of Class)

 Securities to be registered pursuant to Section 12(g) of the Act: NASDAQ OTCBB


                         Preferred Stock Purchase Rights

This Form 8-A/A amends and  supplements  the Form 8-A filed by Miravant  Medical
Technologies,  or the Company,  on July 18, 2000 and as amended on May 24, 2001,
which are referred to in this report as the "Form 8-A".

Item 1. Description of Registrant's Securities to be Registered

     Item 1 of the Form 8-A is amended and supplemented by adding the following:

     On December 31, 2004,  the Board of Directors of the Company  authorized an
amendment to the Preferred Stock Rights Agreement, dated as of July 13, 2000, or
the Rights Agreement,  between the Company and U.S. Stock Transfer  Corporation,
as Rights Agent. The amendment  revises the definition of "Acquiring  Person" in
the Rights  Agreement  to provide  that the none of the  following  entities  is
deemed an  "Acquiring  Person" in  connection  with a transfer  among any of the
following  entities of any shares of the Company's  common stock (or  securities
convertible  into shares of the Company's  common stock)  beneficially  owned by
such entities on the date of the amendment:

                  GORUMNA, LTD. (BVI)
                  PLEYEL HOLDINGS, LIMITED (BVI)
                  BIG CAT CAPITAL, LIMITED (BVI)
                  ACACIAS FINANCIAL, LIMITED (BVI)
                  ALERT INVESTMENTS, LIMITED (BVI)
                  CAMELFORD HOLDINGS, LIMITED (BVI)
                  DANUBE FINANCIAL, LIMITED (BVI)
                  DELICE FINANCIAL, LIMITED (BVI)
                  IRIS FINANCIAL, LIMITED (BVI)
                  PEARL WAVES, INC. (BVI)
                  PRINCESS FINANCE LIMITED, A BVI COMPANY
                  BOMOSEEN INVESTMENTS, LIMITED
                  DANDELION INTERNATIONAL, LIMITED
                  KINARO INVESTMENTS S.A.
                  MOREBATH HOLDINGS, LIMITED
                  SAULES HOLDINGS, LIMITED
                  SILVER CREEK INVESTMENTS, LIMITED
                  ST. CLOUD INVESTMENTS, LIMITED
                  TIOMAN FINANCE, LIMITED

     Each  of  the  foregoing  entities  is an  existing  securityholder  of the
Company.

     The amendment is attached as Exhibit 4.3 hereto and incorporated  herein by
reference.

Item 2.           Exhibits

                  4.1      Preferred Stock Rights Agreement, dated as of July
                           13, 2000, between Miravant Medical Technologies and
                           U.S. Stock Transfer Corporation including the
                           Certificate of Designation, the form of Rights
                           Certificate and the Summary of Rights attached
                           thereto as Exhibits A, B, and C, respectively.
                           (incorporated by reference to Exhibit 4.1 to the
                           Company's Report on Form 8-A, filed July 18, 2000)

                 4.2       Amendment to the Rights Agreement, dated as of April
                           24, 2001, between Miravant Medical Technologies and
                           U.S. Stock Transfer Corporation, as Rights Agent
                           (incorporated by reference to Exhibit 4.1 to the
                           Company's Current Report on Form 8-K, filed May 24,
                           2001)

                 4.3       Amendment  to  the  Rights  Agreement,  dated  as  of
                           December  31,  2004,  between  Miravant  Medical
                           Technologies and U.S. Stock Transfer Corporation,
                           as Rights Agent.  (incorporated by reference to
                           Exhibit 4.1 to the Company's  Current  Report on
                           Form 8-K, filed January 4, 2005)









                                    SIGNATURE

     Pursuant to the  requirements of Section 12 of the Securities  Exchange Act
of 1934, the Registrant has duly caused this registration statement to be signed
on its behalf by the undersigned, thereunto duly authorized.

                                                   Miravant Medical Technologies

 Dated: January 4, 2005                          By:       /s/ John M. Philpott
                                                          --------------------
                                                               John M. Philpott
                                                     Chief Financial Officer